Raid has Ukrainian hemp company at risk, and scared

Raid has Ukrainian hemp company at risk, and scared

Leading Ukranian hemp company Canapteka said law enforcement authorities overstepped their bounds in carrying out a recent raid on its Kiev-based operations in which a…

#CBD #Hemp

Raid has Ukrainian hemp company at risk, and scared

April 2, 2021 9:01 am

Copyright 1994-2023 Richard Rose, all rights reserved. Any views expressed herein are the personal opinion of Richard Rose. This is a noncommercial public service. There are no warranties whatsoever as to the legality, suitability, ownership, purpose, or accuracy of this information. I am not a doctor or a lawyer. If you have medical questions, please seek a medical professional. If you have legal questions, please seek a legal professional. Information found here is not intended to diagnose, cure, treat, or prevent any disease. These statements and subsequent links found here have not been evaluated by the U.S. Food and Drug Administration (FDA). Hemp is not subject to international drug controls and is grown legally around the world. The information posted here is for educational purposes only and is not to be considered legal or medical advice, and is not intended to replace consultation with a qualified legal or medical professional. This website uses cookies. By continuing to use this service, you agree to their use. This is provided on an “as is,” “as available” basis without warranties of any kind, express or implied. The user assumes all responsibility and risk for the use of this website. Links are provided only as an informational resource, and it should not be implied that we own, recommend, endorse or approve of any of the content at the linked sites, nor are we responsible for their content. Unless otherwise stated, nobody pays us nuttin’ to post content, and we have no sponsors unlike NASCAR. By providing your email address to us you agree to be on the free The Richard Rose Report mailing list; you may unsubscribe at any time. There is no charge. To learn more about how we collect, keep, and process your private information in compliance with GDPR, please view our privacy policy via a link at the bottom of this page. Void where prohibited. Specifications subject to change without notice. If you don’t agree with the above please leave immediately. “HempNut,” “The Hemp Nut,” “Hempeh,” “HempRella,” “Not-Pot,” “Nobacco,” “CannaSearch,” “CannaSearch Daily,” “CannaSearch Breaking News,” “The HempNut Cookbook,” “The Richard Rose Report,” “Medicinal Hemp Association,” “Hemp Flower Products Association,” “CannLib,” “CannLib Search,” and the rest of my intellectual property are trademarks, service marks, and/or copyrights of Richard Rose, all rights reserved. All patents, service marks, trademarks, and copyrights are the property of their respective owners. To the best of my knowledge, all Articles, Downloads, and Posts authored by RR are absolutely not written with any type of AI, just a human brain. Grammarly and autocorrect might be used to make minor edits. Posts authored under CannaSearch Daily are written by the original external poster, and no claim is made for those. It’s obvious that GPT language models will be deployed everywhere, but their accuracy is still low so I avoid them for now. Plus writers write.

Perceived Safety and Effectiveness of Cannabis and Other Types of Pain Treatments Among Adults with Chronic Noncancer Pain in U.S. States with Medical Cannabis Programs March 21, 2023
No abstract
Sarah A White
Changes in opioid and benzodiazepine poisoning deaths after cannabis legalization in the US: A county-level analysis, 2002-2020 March 21, 2023
CONCLUSIONS: Implementation of medical cannabis laws was associated with higher rates of opioid- and benzodiazepine-related deaths, while laws permitting broader cannabis access, including implementation of recreational cannabis laws and medical and recreational dispensaries, were associated with lower rates. Estimated effects of expanded availability of cannabis seem dependent on the type of law implemented and its […]
Alvaro Castillo-Carniglia
Intoxications with synthetic cannabinoids March 21, 2023
Synthetic Cannabinoid Receptor Agonists (SCRAs) are a group of New Psychoactive Substances. They are used recreationally to mimic the effects of THC in cannabis. However, THC is a partial agonist of the CB1-receptor and SCRAs are full agonists. Because of this specificity and potency serious adverse events may occur among which psychological, cardiovascular, and gastro-intestinal […]
Jolanda G Zanen
Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report March 21, 2023
CONCLUSIONS: As the availability of delta-8 THC increases, along with associated pediatric exposures, it is imperative for health care providers to quickly recognize and provide adequate treatment. While there is no specific antidote for THC intoxication beyond supportive care, providers can play an important role in prevention by educating parents and guardians on safe cannabis […]
Erin K Bradley
Associations Between Mother-Adolescent and Father-Adolescent Relationships and Young Adult Health March 21, 2023
CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that adolescents' positive perceptions of their relationships with their mothers and fathers are associated with a wide range of favorable outcomes in young adulthood. Investments in improving parent-adolescent relationships may have substantial benefits for young adult population health.
Carol A Ford
Patient Experiences With Prescription Cannabinoids in Germany: Protocol for a Mixed Methods, Exploratory, and Anonymous Web-Based Survey March 21, 2023
CONCLUSIONS: The exploratory mixed methods approach of this project is expected to provide valid and relevant data as a basis for future clinical research. The study design may be representative for a large proportion of outpatients treated with cannabinoids in the German federal states studied. It may have less bias toward social desirability and may […]
Jan Moritz Fischer
Patterns of Event-Level Concurrent Substance Use During Sex Among Gay, Bisexual, and Other Men Who Have Sex with Men in Metro Vancouver March 21, 2023
This study identified patterns of sexualized substance use among gay, bisexual, and other men who have sex with men (gbMSM) and examined associated risk factors for sexually transmitted and blood borne infections (STBBI). Data were from a longitudinal cohort recruited using respondent-driven sampling between Feb-2017 and Feb-2019. Participants reported on events with up to five […]
Kiffer G Card
Cannabinoids as Potential Cancer Therapeutics: The Concentration Conundrum March 21, 2023
Background: Studies have reported that cannabinoids, in particular Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and cannabidiol (CBD), significantly reduce cancer cell viability in vitro. Unfortunately, treatment conditions vary significantly across reports. In particular, a majority of reports utilize conditions with reduced serum concentrations (0-3%) that may compromise the growth of the cells themselves, as well as the observed results. […]
Nurgul Carkaci-Salli
Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state March 20, 2023
Adolescent individuals often present with subtle, sub-threshold psychiatric syndromes that fluctuate or persist for years. These symptoms have been classified as Clinically High-Risk mental states (CHR), negatively affecting these individuals' psychosocial development and integration by reducing performance and affecting interpersonal relations. The pathophysiological underpinnings have not been studied in detail, contributing to the current lack […]
Dagmar Koethe
The minor cannabinoid cannabigerol (CBG) is a highly specific blood biomarker of recent cannabis smoking March 20, 2023
CONCLUSION: Whole blood cannabigerol may have forensic utility as a highly specific albeit insensitive biomarker of recent cannabis smoking.
John M Rague
An exploratory follow-up study of cannabis use and decision-making under various risk conditions within adolescence March 20, 2023
CONCLUSIONS: DM under explicit risk may be a more salient risk factor for escalating CU and CU-related problems than DM under ambiguous risk. Deficits in executive functioning could partially explain the results. Findings suggest that neurocognitive development should inform prevention and intervention efforts focused on reducing CU. Given the exploratory nature of the present study, […]
Erin L Thompson
Cannabinoids in traumatic brain injury and related neuropathologies: preclinical and clinical research on endogenous, plant-derived, and synthetic compounds March 20, 2023
Traumatic brain injury is common, and often results in debilitating consequences. Even mild traumatic brain injury leaves approximately 20% of patients with symptoms that persist for months. Despite great clinical need there are currently no approved pharmaceutical interventions that improve outcomes after traumatic brain injury. Increased understanding of the endocannabinoid system in health and disease […]
Brittney R Lins
Efficient Syntheses of KLS-13019 Using Palladium Mediated Cross Couplings March 20, 2023
KLS-13019 is a structural analogue of cannabidiol, that shows improved bioavailability and potency in both preventing and reversing paclitaxel-induced neurotoxicity in vitro and in vivo. KLS-13019 was selected as a development candidate and attention was turned to development of a scalable synthesis. The original synthesis of KLS-13019 was not efficient, regioselective, or high yielding. Two […]
William A Kinney
Medical cannabis identity and public health paternalism March 20, 2023
CONCLUSIONS: The designation of medical vs. nonmedical use of cannabis varies from state to state, which is not the case for other medicine. This highly variable designation may be paternalistic in nature as governments attempt to differentiate between "legitimate" and "illegitimate" use in the context of federal cannabis prohibition. As a result, lines between medical […]
Amanda Reiman
Incidence of cardiovascular symptoms and adverse events following self-reported acute cannabis intoxication at the emergency department: a retrospective study March 20, 2023
No abstract
Femke Gresnigt
Are Drinking Cognitions Associated with Marijuana and Concurrent Alcohol and Marijuana Use among Adolescents and Young Adults? March 20, 2023
CONCLUSIONS: Findings support and extend the utility of the PWM by indicating that specific alcohol cognitions are associated with alcohol, marijuana, and CAM use in adolescents and young adults.
Ricarda K Pritschmann
High-CBD Cannabis Vapor Attenuates Opioid Reward and Partially Modulates Nociception in Female Rats March 20, 2023
Chronic pain patients report analgesic effects when using cannabidiol (CBD), a phytocannabinoid found in whole-plant cannabis extract (WPE). Several studies suggest that cannabis-derived products may serve as an analgesic adjunct or alternative to opioids, and importantly, CBD may also attenuate the abuse potential of opioids. Vaping is a popular route of administration among people who […]
Maria T Rivera-Garcia
Cannabis Use Does Not Affect Outcomes After Total Hip Arthroplasty March 20, 2023
CONCLUSION: Self-reported cannabis use does not influence one-year outcomes after THA. Further studies are warranted to determine the efficacy and safety of perioperative cannabis use after THA to help guide orthopaedic surgeons in counseling patients.
Vishal Hegde
Expression of cannabinoid (CB1 and CB2) and cannabinoid-related receptors (TRPV1, GPR55, and PPARα) in the synovial membrane of the horse metacarpophalangeal joint March 20, 2023
CONCLUSIONS AND CLINICAL IMPORTANCE: Given the expression of the CB1R, CB2R, TRPV1, GPR55, and PPARα in the synovial elements of the metacarpophalangeal joint, these findings encouraged the development of new studies supporting the use of molecules acting on these receptors to reduce the inflammation during joint inflammation in the horse.
Rodrigo Zamith Cunha
Cognitive behavioral therapy for insomnia to reduce cannabis use: Results from a pilot randomized controlled trial March 20, 2023
CONCLUSIONS: CBTi-CB-TM is feasible, acceptable, and demonstrated preliminary efficacy for improving sleep and cannabis-related outcomes among non-treatment-seeking individuals with regular cannabis use for sleep. Although sample characteristics limit generalizability, these findings support the need for adequately powered randomized controlled trials with longer follow-up periods.
J Todd Arnedt